PET100 cytochrome c oxidase chaperoneGenealiases: C19orf79 · MC4DN12
Q-omics provides the consensus-scored PET100 profile across patient tissues and cancer cell-line models. PET100 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PET100 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PET100 RNA expression shows 18,365 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KIRC, and THYM as cancer lineages where PET100 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PET100 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PET100 survival associations across molecular data types. PET100 RNA expression shows survival associations in the most cancer types (28), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PET100 RNA expression–survival associations across cancer types. High PET100 expression shows unfavorable associations in ACC, UVM, ESCA and UCS, but favorable associations in CESC and BLCA. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for PET100 RNA expression.
This table summarizes PET100 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PET100. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PET100 shows lower tumor expression in LUAD and higher tumor expression in KIRC, LIHC, BLCA, BRCA and CHOL. The KIRC box plot shows higher PET100 RNA expression in tumor versus normal tissue (log2 FC = +0.244, t-test p < 0.001).
This table shows molecular features associated with PET100 in patient tissues and cancer cell lines. In patient samples, PET100 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PET100 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
